{
  "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "docSlug": "5062b9a9257606648ea145bccd66e04d",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 41,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a matrix-like comparison to highlight the unique value proposition of NVL-520 compared to standard-of-care drugs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/28",
  "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "deckJsonHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json",
  "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.35,
        "x": 0.625,
        "y": 0.21
      },
      "kind": "callout",
      "text": "NVL-520 Preliminary Phase 1 Conclusions (Drilon A. et al., EORTC-NCI-AACR 2022)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab9eabd2-3e5d-47a4-a657-d0402f708042",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Source: Drilon A. et al., EORTC-NCI-AACR 2022. Head-to-head clinical studies comparing NVL-520 with currently approved or investigational therapies have not been conducted.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "facec28b-90d3-4fa4-b361-46eb996567ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "table",
      "text": "Comparison matrix of ROS1 inhibitors (Crizotinib, Entrectinib, Lorlatinib, Repotrectinib, Taletrectinib) vs NVL-520 across ROS1 activity, Mutant activity, CNS activity, and TRK sparing.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af815192-5216-4b87-a45d-e362d81d8067",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "NVL-520: A Rationally Designed ROS1-selective, TRK-sparing Inhibitor",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ddc2c36-d8f2-4ab9-847a-4cd8fbae21c2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "565de599-306c-4a0f-9e04-1f5fa33c72a5",
      "evidence": "Comparison of drug features across multiple competitors",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}